# Fluence Energy, Inc.: financial statements, quarterly FLNC · Nasdaq · CIK 1868941 · [Technology](/sectors/technology.md) · fiscal year ends Sep 30 Pages: [Overview](/companies/flnc.md) · [Financials](/companies/flnc/financials.md) · [Filings](/companies/flnc/filings.md) · [Insiders](/companies/flnc/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/flnc/financials.md?period=annual). ## Income statement | Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [673 d](/filings/0001868941-25-000081.md) | [364](/filings/0001868941-25-000015.md) | [623](/filings/0001868941-25-000060.md) | [483](/filings/0001868941-25-000076.md) | [1,228 d](/filings/0001868941-25-000081.md) | [187](/filings/0001868941-26-000005.md) | [432](/filings/0001104659-26-056304.md) | [603](/filings/0001868941-26-000029.md) | [1,042 d](/filings/0001868941-25-000081.md) | [475](/filings/0001868941-26-000005.md) | [465](/filings/0001104659-26-056304.md) | [650](/filings/0001868941-26-000029.md) | | Cost of revenue | $m | [597 d](/filings/0001868941-25-000081.md) | [328](/filings/0001868941-25-000015.md) | [559](/filings/0001868941-25-000060.md) | [400](/filings/0001868941-25-000076.md) | [1,071 d](/filings/0001868941-25-000081.md) | [166](/filings/0001868941-26-000005.md) | [389](/filings/0001104659-26-056304.md) | [513](/filings/0001868941-26-000029.md) | [899 d](/filings/0001868941-25-000081.md) | [452](/filings/0001868941-26-000005.md) | [418](/filings/0001104659-26-056304.md) | [617](/filings/0001868941-26-000029.md) | | Gross profit | $m | [76.3 d](/filings/0001868941-25-000081.md) | [36.4](/filings/0001868941-25-000015.md) | [64.2](/filings/0001868941-25-000060.md) | [83.0](/filings/0001868941-25-000076.md) | [157 d](/filings/0001868941-25-000081.md) | [21.2](/filings/0001868941-26-000005.md) | [42.6](/filings/0001104659-26-056304.md) | [89.1](/filings/0001868941-26-000029.md) | [143 d](/filings/0001868941-25-000081.md) | [23.0](/filings/0001868941-26-000005.md) | [46.6](/filings/0001104659-26-056304.md) | [33.2](/filings/0001868941-26-000029.md) | | Research and development | $m | [14.7 d](/filings/0001868941-25-000081.md) | [15.4](/filings/0001868941-25-000015.md) | [17.4](/filings/0001868941-25-000060.md) | [15.0](/filings/0001868941-25-000076.md) | [18.4 d](/filings/0001868941-25-000081.md) | [17.2](/filings/0001868941-26-000005.md) | [22.1](/filings/0001104659-26-056304.md) | [26.0](/filings/0001868941-26-000029.md) | [20.9 d](/filings/0001868941-25-000081.md) | [18.5](/filings/0001868941-26-000005.md) | [21.1](/filings/0001104659-26-056304.md) | [23.7](/filings/0001868941-26-000029.md) | | Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Income tax | $m | [6.6 d](/filings/0001868941-25-000081.md) | [(1.2)](/filings/0001868941-25-000015.md) | [(1.7)](/filings/0001868941-25-000060.md) | [4.2](/filings/0001868941-25-000076.md) | [7.9 d](/filings/0001868941-25-000081.md) | [(1.7)](/filings/0001868941-26-000005.md) | [(2.0)](/filings/0001104659-26-056304.md) | [4.6](/filings/0001868941-26-000029.md) | [22.0 d](/filings/0001868941-25-000081.md) | [(7.9)](/filings/0001868941-26-000005.md) | [1.5](/filings/0001104659-26-056304.md) | [0.8](/filings/0001868941-26-000029.md) | | Net income | $m | [3.3 d](/filings/0001868941-25-000081.md) | [(16.7)](/filings/0001868941-25-000015.md) | [(9.2)](/filings/0001868941-25-000060.md) | [0.8](/filings/0001868941-25-000076.md) | [47.8 d](/filings/0001868941-25-000081.md) | [(41.5)](/filings/0001868941-26-000005.md) | [(31.0)](/filings/0001104659-26-056304.md) | [6.3](/filings/0001868941-26-000029.md) | [17.9 d](/filings/0001868941-25-000081.md) | [(45.1)](/filings/0001868941-26-000005.md) | [(20.9)](/filings/0001104659-26-056304.md) | [(32.8)](/filings/0001868941-26-000029.md) | | Diluted EPS | $ per share | not reported | [(0.14)](/filings/0001868941-25-000015.md) | [(0.07)](/filings/0001868941-25-000060.md) | [0.00](/filings/0001868941-25-000076.md) | not reported | [(0.32)](/filings/0001868941-26-000005.md) | [(0.24)](/filings/0001104659-26-056304.md) | [0.01](/filings/0001868941-26-000029.md) | not reported | [(0.34)](/filings/0001868941-26-000005.md) | [(0.16)](/filings/0001104659-26-056304.md) | [(0.24)](/filings/0001868941-26-000029.md) | | Basic EPS | $ per share | not reported | [(0.14)](/filings/0001868941-25-000015.md) | [(0.07)](/filings/0001868941-25-000060.md) | [0.01](/filings/0001868941-25-000076.md) | not reported | [(0.32)](/filings/0001868941-26-000005.md) | [(0.24)](/filings/0001104659-26-056304.md) | [0.05](/filings/0001868941-26-000029.md) | not reported | [(0.34)](/filings/0001868941-26-000005.md) | [(0.16)](/filings/0001104659-26-056304.md) | [(0.24)](/filings/0001868941-26-000029.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Interest expense: not reported - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [346](/filings/0001868941-24-000070.md) | [318](/filings/0001868941-24-000014.md) | [412](/filings/0001868941-24-000045.md) | [388](/filings/0001868941-24-000059.md) | [449](/filings/0001868941-25-000081.md) | [607](/filings/0001868941-25-000015.md) | [569](/filings/0001868941-25-000060.md) | [436](/filings/0001868941-25-000076.md) | [691](/filings/0001868941-26-000029.md) | [453](/filings/0001868941-26-000005.md) | [387](/filings/0001104659-26-056304.md) | [339](/filings/0001868941-26-000029.md) | | Current assets | $m | [1,195](/filings/0001868941-24-000070.md) | [1,665](/filings/0001868941-24-000014.md) | [1,323](/filings/0001868941-24-000045.md) | [1,504](/filings/0001868941-24-000059.md) | [1,680](/filings/0001868941-25-000081.md) | [1,984](/filings/0001868941-25-000015.md) | [2,031](/filings/0001868941-25-000060.md) | [1,850](/filings/0001868941-25-000076.md) | [2,064](/filings/0001868941-26-000029.md) | [1,987](/filings/0001868941-26-000005.md) | [2,082](/filings/0001104659-26-056304.md) | [2,325](/filings/0001868941-26-000029.md) | | Total assets | $m | [1,352](/filings/0001868941-24-000070.md) | [1,815](/filings/0001868941-24-000014.md) | [1,530](/filings/0001868941-24-000045.md) | [1,690](/filings/0001868941-24-000059.md) | [1,902](/filings/0001868941-25-000081.md) | [2,214](/filings/0001868941-25-000015.md) | [2,273](/filings/0001868941-25-000060.md) | [2,075](/filings/0001868941-25-000076.md) | [2,357](/filings/0001868941-26-000029.md) | [2,270](/filings/0001868941-26-000005.md) | [2,348](/filings/0001104659-26-056304.md) | [2,616](/filings/0001868941-26-000029.md) | | Current liabilities | $m | [746](/filings/0001868941-24-000070.md) | [1,252](/filings/0001868941-24-000014.md) | [973](/filings/0001868941-24-000045.md) | [1,125](/filings/0001868941-24-000059.md) | [1,259](/filings/0001868941-25-000081.md) | [1,261](/filings/0001868941-25-000015.md) | [1,345](/filings/0001868941-25-000060.md) | [1,125](/filings/0001868941-25-000076.md) | [1,370](/filings/0001868941-26-000029.md) | [1,340](/filings/0001868941-26-000005.md) | [1,451](/filings/0001104659-26-056304.md) | [1,734](/filings/0001868941-26-000029.md) | | Total liabilities | $m | [796](/filings/0001868941-24-000070.md) | [1,276](/filings/0001868941-24-000014.md) | [998](/filings/0001868941-24-000045.md) | [1,152](/filings/0001868941-24-000059.md) | [1,295](/filings/0001868941-25-000081.md) | [1,685](/filings/0001868941-25-000015.md) | [1,774](/filings/0001868941-25-000060.md) | [1,554](/filings/0001868941-25-000076.md) | [1,808](/filings/0001868941-26-000029.md) | [1,781](/filings/0001868941-26-000005.md) | [1,890](/filings/0001104659-26-056304.md) | [2,184](/filings/0001868941-26-000029.md) | | Long-term debt | $m | [28.0](/filings/0001868941-24-000070.md) | [0.0](/filings/0001868941-24-000014.md) | [0.0](/filings/0001868941-24-000045.md) | [0.0](/filings/0001868941-24-000059.md) | [0.0](/filings/0001868941-24-000070.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Current portion of debt | $m | [22.5](/filings/0001868941-24-000070.md) | [51.6](/filings/0001868941-24-000014.md) | [59.0](/filings/0001868941-24-000045.md) | [53.7](/filings/0001868941-24-000059.md) | [30.4](/filings/0001868941-25-000081.md) | [0.0](/filings/0001868941-25-000015.md) | [0.0](/filings/0001868941-25-000060.md) | [0.0](/filings/0001868941-25-000076.md) | [0.0](/filings/0001868941-25-000081.md) | not reported | not reported | not reported | | Shareholders' equity | $m | [402](/filings/0001868941-24-000070.md) | [416](/filings/0001868941-24-000014.md) | [413](/filings/0001868941-24-000045.md) | [421](/filings/0001868941-24-000059.md) | [472](/filings/0001868941-25-000081.md) | [409](/filings/0001868941-25-000015.md) | [388](/filings/0001868941-25-000060.md) | [407](/filings/0001868941-25-000076.md) | [430](/filings/0001868941-26-000029.md) | [388](/filings/0001868941-26-000005.md) | [368](/filings/0001104659-26-056304.md) | [373](/filings/0001868941-26-000029.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: us-gaap:LongTermDebtCurrent - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [48.6 d](/filings/0001868941-25-000081.md) | [19.4](/filings/0001868941-25-000015.md) | [70.9 d](/filings/0001868941-25-000060.md) | [(21.1) d](/filings/0001868941-25-000076.md) | [10.5 d](/filings/0001868941-25-000081.md) | [(211)](/filings/0001868941-26-000005.md) | [(46.2) d](/filings/0001104659-26-056304.md) | [(154) d](/filings/0001868941-26-000029.md) | [266 d](/filings/0001868941-25-000081.md) | [(227)](/filings/0001868941-26-000005.md) | [(121) d](/filings/0001104659-26-056304.md) | [(18.6) d](/filings/0001868941-26-000029.md) | | Capital expenditure | $m | [1.1 d](/filings/0001868941-25-000081.md) | [1.5](/filings/0001868941-25-000015.md) | [1.0 d](/filings/0001868941-25-000060.md) | [2.4 d](/filings/0001868941-25-000076.md) | [3.3 d](/filings/0001868941-25-000081.md) | [2.1](/filings/0001868941-26-000005.md) | [4.4 d](/filings/0001104659-26-056304.md) | [3.6 d](/filings/0001868941-26-000029.md) | [4.9 d](/filings/0001868941-25-000081.md) | [5.8](/filings/0001868941-26-000005.md) | [2.5 d](/filings/0001104659-26-056304.md) | [1.4 d](/filings/0001868941-26-000029.md) | | Share repurchases | $m | [1.2 d](/filings/0001868941-23-000085.md) | [0.0](/filings/0001868941-24-000014.md) | [0.1 d](/filings/0001868941-24-000045.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q1 FY2023 (2022-12-31) | Q2 FY2023 (2023-03-31) | Q3 FY2023 (2023-06-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [115](/filings/0001868941-24-000014.md) | [116](/filings/0001868941-24-000045.md) | [117](/filings/0001868941-24-000059.md) | [121](/filings/0001868941-25-000015.md) | [127](/filings/0001868941-25-000060.md) | [184](/filings/0001868941-25-000076.md) | [129](/filings/0001868941-26-000005.md) | [130](/filings/0001104659-26-056304.md) | [184](/filings/0001868941-26-000029.md) | [132](/filings/0001868941-26-000005.md) | [133](/filings/0001104659-26-056304.md) | [138](/filings/0001868941-26-000029.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.